FDA Oncology Center of Excellence director R. Angelo de Claro stated that review of shared cancer features allowed the agency to expand treatment options for papillary tumors

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Cancer treatment modalities including targeted therapy, immunotherapy, biologic therapies, and AI-driven treatment approaches.